Your Health, We Care
The efficacy of Cibinqo as monotherapy and in combination with background topical corticosteroids was evaluated in 4 randomized, double-blind, placebo-controlled trials [Trial-AD-1 (NCT03349060), Trial-AD-2 (NCT03575871), Trial-AD-3 (NCT03720470), and Trial-AD-4 (NCT03796676)] in 1900 subjects (see Table 8). Trial-AD-1 and Trial-AD-2 enrolled adult and pediatric subjects 12 years of age and older.
Trial-AD-1, Trial-AD-2, Trial-AD-3, and Trial-AD-4 assessed the co-primary endpoints of IGA and EASI-75 responses at Week 12. The designs of the trials are summarized in Table 8.
The results of the Cibinqo monotherapy trials (Trial-AD-1 and Trial-AD-2) are presented next.
The proportion of subjects achieving PP-NRS4 at Week 2 (defined as an improvement of-4 points from baseline in PP-NRS) was higher in subjects treated with Cibinqo monotherapy 200 mg once daily (28% in Trial-AD-1 and 24% in Trial-AD-2) and 100 mg once daily (11% in both trials) compared to placebo (2% in both trials).
A higher proportion of subjects in the Cibinqo monotherapy 100 mg or 200 mg once daily arms compared to placebo achieved improvement in itching at Week 12.
The results of Cibinqo in combination with background topical corticosteroids in subjects 18 years of age and older (Trial-AD-3) are presented in next.
The proportions of subjects achieving PP-NRS4 at Week 2 was higher in subjects treated with Cibinqo 200 mg once daily (30%) and 100 mg once daily (14%) in combination with background medicated topical therapies compared to placebo (8%).
The proportion of pediatric subjects 12 to less than 18 years of age achieving PP-NRS4 at Week 2 in Trial-AD- 4 was higher with Cibinqo 200 mg once daily (25%) and 100 mg once daily (13%) compared to placebo (8%).
A higher proportion of subjects in the Cibinqo 200 mg once daily arm compared to placebo achieved improvement in itching at Week 12.
from FDA，2023.12
